General Electric is selling its biopharma business to Danaher Corp. for $21.4b. The deal complements Danaher's current biologics workflow solutions. GE’s biopharma business includes process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and related services.
GE...
Read More
Large pharmaceutical and diagnostic players companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, some with limited revenue.
In March 2019, Thermo Fisher Scientific agreed to pay $1.7b to acquire Brammer Bio, which offers pre-clinical and analytical development, process...
Read More
Catalent, Inc., a $2.46b provider of delivery technologies for drugs, biologics, and consumer and animal health products, is buying Paragon Bioservices, Inc., a developer of viral vectors for gene therapies. The deal Complements Catalent's biologics business. Paragon engages in the production and purification of therapeutic proteins, monoclonal...
Read More
Smith & Nephew plc (LSE:SN, NYSE:SNN), a $4.9b maker of orthopedic, wound management, sports medicine and trauma & extremities products, is acquiring Osiris Therapeutics, Inc., a provider of regenerative medicine products, including skin, bone graft and articular cartilage substitutes. The deal accelerates S&N's wound management...
Read More
Medtronic plc (NYSE: MDT), a $29.95b manufacturer of cardio-vascular, orthopedic, spinal and other medical devices., is buying EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics), a maker of a catheter-based, temperature-controlled cardiac ablation systems. The acquisition expands Medtronic's cardiac ablation portfolio. EPIX...
Read More